Opinion|Videos|January 24, 2025
Time-Limited Therapy with Venetoclax-Obinutuzumab: Rationale and Data
Panelists discuss, role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly discuss role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.
Advertisement
Related to this article
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 and how they may shake up the CLL treatment paradigm.
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC
4
Zoldonrasib Combinations Show Compelling Antitumor Activity in RAS G12D–Mutant Metastatic PDAC
5